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Autosomal-Dominant Striatal Degeneration
Is Caused by a Mutation
in the Phosphodiesterase 8B Gene
Silke Appenzeller,1,9 Anja Schirmacher,2,9 Hartmut Halfter,2 Sebastian Ba¨umer,2 Manuela Pendziwiat,2
Vincent Timmerman,3 Peter De Jonghe,3 Kla´ra Fekete,4 Florian Sto¨gbauer,5 Peter Lu¨demann,6
Margret Hund,7 Elgar Susanne Quabius,8 E. Bernd Ringelstein,2 and Gregor Kuhlenba¨umer1,*
Autosomal-dominant striatal degeneration (ADSD) is an autosomal-dominant movement disorder affecting the striatal part of the basal
ganglia. ADSD is characterized by bradykinesia, dysarthria, and muscle rigidity. These symptoms resemble idiopathic Parkinson disease,
but tremor is not present. Using genetic linkage analysis, we have mapped the causative genetic defect to a 3.25 megabase candidate
region on chromosome 5q13.3-q14.1. A maximum LOD score of 4.1 (Q ¼ 0) was obtained at marker D5S1962. Here we show that
ADSD is caused by a complex frameshift mutation (c.94G>Cþc.95delT) in the phosphodiesterase 8B (PDE8B) gene, which results
in a loss of enzymatic phosphodiesterase activity. We found that PDE8B is highly expressed in the brain, especially in the putamen,
which is affected by ADSD. PDE8B degrades cyclic AMP, a second messenger implied in dopamine signaling. Dopamine is one of
the main neurotransmitters involved in movement control and is deﬁcient in Parkinson disease. We believe that the functional
analysis of PDE8B will help to further elucidate the pathomechanism of ADSD as well as contribute to a better understanding of move-
ment disorders.Autosomal-dominant striatal degeneration (ADSD [MIM
609161]) is a rare autosomal-dominant disease affecting
the striatal part of the basal ganglia.1 The main clinical
features of ADSD are slowly progressive dysarthria, brady-
kinesia presenting predominantly as gait disturbance,
and muscle rigidity as well as diadochokinesis. Tremor is
not present. In contrast to Parkinson disease (PD [MIM
168600]), the patients do not show a good response to
L-Dopa therapy. The age of onset of clinical symptoms is
in the fourth to ﬁfth decade, with no apparent reduction
in life expectancy. Brain MRIs show distinctive lesions
of the striatum (putamen, caudate nucleus, and nucleus
accumbens) appearing earlier than the onset of symptoms.
MRI abnormalities consist primarily of a signal increase on
T2-weighted images (Figure 1A) and a corresponding signal
decrease on T1-weighted images.1
To identify the gene underlying the ADSD phenotype in
an ADSD family, we followed a classical linkage-analysis
approach. Seventeen members of a German ADSD family
(Figure 1B) underwent neurologic examination and
received T1- and T2-weighted spin-echoMRI examinations
at 1.5 Tesla.1 DNA was isolated from white blood cells via
standard protocols. Seventeen individuals, seven of whom
are affected, were included in the initial genome scan and
the ﬁne mapping as described previously.1 The study was
approved by the ethics committee of the University of
Muenster, Germany, and informed consent was obtained.
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The Amosome 5q13.3-14.1 by genome-wide linkage analysis
(see Tables S1 and S2 available online). A maximum LOD
score of 4.1 (Q¼ 0) was obtained at marker D5S1962. Anal-
ysis of 34 additional short tandem repeat (STR) markers
within the candidate region with an average intermarker
distance of 70 kb did not allow further reduction of the
candidate region (Table S2). Primer sequences for the STR
markers used in the delineation of the candidate region
are listed in Table S3. PCR conditions are available upon
request.
STR markers did not show triple alleles or hemizygosity,
arguing against large duplications or deletions causing
ADSD (data not shown).
The candidate region contained 21 known RefSeq anno-
tated protein-coding genes (Figure 2A). Positional candi-
date genes were obtained from the RefSeq database with
the UCSC Human Genome Browser (hg18). Coding exons
and intronic ﬂanking regions of all protein coding genes
in the candidate region were analyzed for sequence varia-
tions by direct DNA sequencing. Sequences included about
30–100 base pairs (bp) of intronic sequence for detection of
splice-site mutations. Primer sequences were based on the
reference sequenceof eachgenedeposited inRefSeq. Primer
sequences for the phosphodiesterase 8B gene (PDE8B [MIM
603390]) are given in Table S4. The genomic structure of
PDE8B is shown in Figure 2B. Sequence analysis was per-
formed with the BigDye Terminator Cycle Sequencing Kit
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Figure 1. MRI Features and Pedigree of the ADSD Family
(A) T2-weighted images of a healthy control (left) and ADSD patient III:5 (right; encircled are regions of pathologic signal increase).
(B) Pedigree of the ADSD family. Clear symbols represent unaffected individuals. Filled symbols represent individuals with ADSD. Indi-
viduals were considered affected on the basis of the characteristic symmetric MRI abnormalities of the basal ganglia. The index patient
(IV:2, arrow) is shown inMovie S1. Segregation analysis showed perfect cosegregation of the PDE8Bmutation (c.94G>Cþc.95delT) with
ADSD. þ/m denotes heterozygous mutation carriers; þ/þ denotes individuals homozygous for the wild-type allele.a 3730 DNA Analyzer (Applied Biosystems) and analyzed
with the ‘‘Seqman’’ module from the DNASTAR package
(DNASTAR, Inc.). We detected a heterozygote sequence
variation (c.94G>Cþc.95delT) (Figure 2C) in the ﬁrst
exon of PDE8B (NM_003719). Five hundred unrelated
healthy controlswere analyzed for theADSD-causingmuta-
tion, 200 by direct sequencing and 300 by PCR restriction
fragment-length polymorphism. PCR primers were as
follows: forward, 50-CAGAGCGGCGTGATCTACT-30; and
reverse, 50-GTGTAGCAGGTCTGAGTCTCG-30. The PCR
product of 299 bp (wild-type) or 298 bp (mutant) was
digested with the restriction enzyme OliI (Fermentas),
resulting in two fragments of 61 and 238 bp for the wild-
type allele. The PCR product of the mutant allele was not
digested by OliI. This sequence variation segregates with
ADSDandwas foundneither in the 500 ethnicallymatched
control individuals nor in the sequence-variation database
dbSNP. No other potentially ADSD-causing mutation was
detected in any of the 21 candidate genes. These results
strongly argue that ADSD is caused by the PDE8Bmutation.
However, these data would be strengthened further if
a second familywithADSDhadbeen available for the study.
The frameshift mutation alters the amino acid se-
quence of the PDE8B protein C terminus of amino acid
31 and introduces a premature stop after 63 amino acids
(NM_003719) (Figures 2E and 2F). Phosphodiesterases
(PDEs) regulate the localization, duration, and amplitude
of cyclic nucleotide signaling within subcellular compart-
ments. The intracellular levels of cyclic AMP (cAMP) and
cyclic guanosine monophosphate (cGMP) are controlled
by their rates of synthesis as well as by their rates of degra-84 The American Journal of Human Genetics 86, 83–87, January 8, 20dation by phosphodiesterases. Eleven distinct PDE protein
families have been described in humans.2 All PDEs share
a conserved C-terminal catalytic region but have highly
variable N termini composed of different domains that
presumably confer distinct regulatory properties to the
individual PDE families.2 The conserved PDE catalytic
domain is composed of 270–300 amino acids located in
the C-terminal part of each PDE.3 PDE8B is a cAMP-speciﬁc
isobutyl-1-methylxanthine (IBMX)-insensitive phospho-
diesterase that catalyzes the hydrolysis of the second
messenger 30,50-cAMP to 50-AMP.3 PDE8B is composed of
23 exons.4,5 Six alternative splice variants are known
(Figure 2B; Table S5). The longest isoform (PDE8B1)
encodes a protein of 885 amino acids containing an N-
terminal REC (cheY-homologous receiver) domain, a PAS
(Per, Arnt, and Sim) domain, and a C-terminal catalytic
PDE domain (Figure 2D).3 The functions of the PAS and
the REC domains in PDE8B are unknown.4 Isoforms 2
and 3 lack part of the PAS domain, but all isoforms contain
the REC and the catalytic PDE domain. The REC, PAS, and
PDE domains show very high interspecies amino acid
conservation (human versus mouse: 98.6%), suggesting
an important function of these domains.
The ADSD-causing mutation results in a loss of all three
functional domains of PDE8B (Figures 2D and 2E), which
most likely causes a complete loss of function of the trun-
cated protein. To prove the loss of phosphodiesterase
enzymatic activity of mutated PDE8B, we transfected
COS-7 cells with isoform 1 of wild-type PDE8B (pEGFP-
PDE8BWt),mutated PDE8B (pEGFP-PDE8B-Mut), or empty
vector (pEGFP). COS-7 cells were cultivated in Dulbecco’s10
Figure 2. ADSD Candidate Region, Genomic Organization of PDE8B, PDE8BMutation Found in the ADSD Family, Structural and Func-
tional Consequences for the Protein
(A) The 3.25 Mb candidate region with locations of all 21 RefSeq annotated protein coding genes.
(B) Genomic organization of the different PDE8B variants. The localization of the ADSD-causing mutation in exon 1 is indicated by an
arrow. Accession numbers of PDE8B isoforms are given in Table S4.
(C) Complex (c.94G>Cþc.95delT) mutation found in the ADSD family. Shown is the reverse sequence.
(D) Protein structure of PDE8B and position of the functional domains REC, PAS, and PDE in PDE8B isoform 1.
(E) Structure of the truncated protein. The altered amino acid sequence starting at residue 32 is shaded.
(F) Amino acid sequence of the truncated protein. Residues 1–31 (upper row, black) and altered residues 32–63 (lower row, red) are shown.
(G) Effects of the PDE8B mutation on cAMP levels. All error bars indicate standard deviation (SD). Each sample was run in triplicate
(n ¼ 3) and the experiment was repeated three times. * indicates a signiﬁcant difference between wild-type and mutant (p < 0.05)
and wild-type and empty vector (p < 0.01). The difference between mutant and empty vector was not signiﬁcant. Luminescence
(RLU) is inversely proportional to cAMP levels. High PDE8B activity results in low cAMP concentration, leading to high luminescence.modiﬁed Eagle’s medium high glucose with L-Glutamine
and with sodium pyruvate (Th. Geyer) supplemented with
5% fetal calf serum (Invitrogen) and 1% Pen/Strep-Premix
(Carl-Roth) at 37C with 5% CO2. Transfections were per-
formed with either Turbofect (Fermentas) or Nanofect
(PAA Laboratories) according to the manufacturers’ recom-
mendations. A full open reading frame clone containing
wild-type PDE8B isoform 1 was obtained from Imagenes.
The ADSD-causing mutation (c.94G>Cþc.95delT) was
introduced with the QuickChange XL Site-Directed Muta-
genesis Kit (Stratagene). Wild-type and mutant PDE8B
were PCR ampliﬁed via primers containing HindIII and
EcoR1 sites. The PCR products were subcloned into
pEGFP-N3 (Clontech) to generate constructs expressing
PDE8B C-terminally fused to enhanced green ﬂuorescent
protein (EGFP). The inserts of all constructs were veriﬁed
by DNA sequencing.The AQuantitative determination of cAMP was carried out
via the cAMP-Glo Assay (Promega). A total of 20,000
COS-7 cells were grown in poly-D-lysine-coated, white,
clear-bottom, 96-well plates (Nunc). After 24 hr, the cells
were transfected with 0.2 mg of plasmid. Then, 24 hr
after transfection, cells were incubated with induction
buffer (2000 mM IBMX), 400 mM 4-(3-butoxy-4-methoxy-
benzyl) imidazolidone (Ro 20-1724), and 18 mM Forskolin
(all from Sigma-Aldrich) in PBS, pH 7.4 (Invitrogen) for
30 min at 37C. The assay was performed according to
the recommendations of the manufacturer. Lumines-
cence was measured with a TRIAD plate reader (Dynex
Technologies).
All experiments were performed three times, and each
samplewas run in triplicate (n¼ 3). Error bars indicate stan-
dard deviations. Statistical differences were determined by
one-way analysis of variance with Bonferroni correctionmerican Journal of Human Genetics 86, 83–87, January 8, 2010 85
Figure 3. Expression of PDE8B
Relative quantiﬁcation of PDE8B in various human tissues by real-
time PCR and standard deviation. Quantiﬁcation was performed
with ACTB, GAPDH, and PPIA as reference genes. All error bars
indicate SD. Each sample was run in triplicate (n ¼ 3).for multiple testing. Statistical signiﬁcance was assumed
at p < 0.05.
Although overexpressing wild-type PDE8B in COS-7
cells signiﬁcantly reduced cAMP levels compared to the
empty vector control, mutated PDE8B was not distinguish-
able from empty vector (Figure 2G). Protein expression
levels were determined qualitatively by immunoblot anal-
ysis. COS-7 cells were seeded in 6 well plates (80 3 103 per
well) and transfected after 24 hr with 2.5 mg plasmid DNA.
Cells were lysed in SDS buffer. After measuring protein
concentration, 50 mg of protein lysate was run on a 10%
SDS gel. The gels were blotted onto a polyvinylidene ﬂuo-
ride (PVDF) membrane incubated with the antibodies after
blocking. Polyclonal anti-GFP antibody (Invitrogen) was
used in a 1:2000 dilution. The blot was then incubated
with horseradish conjugated goat anti-rabbit antibody
(Bio-Rad) diluted 1:30,000. SuperSignal West Pico Sub-
strate Kit (Fisher Scientiﬁc) was used as chemiluminescent
substrate. Signals were detected via a Chemoluminescence
Imager (Biozym). Immunoblotting demonstrated that the
expression levels of wild-type PDE8B were consistently
lower than those of mutant PDE8B (Figure S1A). Therefore,
the difference in enzymatic activity between wild-type
and mutant PDE8B is underestimated in our analysis. As
expected, the ADSD-causing mutation results in a loss of
phosphodiesterase activity.
PDE8B expression has been reported in thyroid gland,
brain, placenta, pancreas, and adrenal cortex.4,5 Previous
studies suggest that PDE8B expression is higher in brain
regions affected by ADSD (caudate nucleus and putamen)
than in most other regions of the brain (e.g., cerebellum).6
To conﬁrm and extend these ﬁndings, we assessed PDE8B
expression in different human tissues by quantitative
real-time PCR (qPCR). RNA was either purchased (Clon-
tech) or isolated with Trizol (Invitrogen) or the RNeasy
Mini Kit (QIAGEN). RNA was reverse transcribed with the
QuantiTect Reverse Transcription Kit (QIAGEN). PDE8B
primers were as follows: forward, 50-CTGTGGTGATGCCA
GTGTT-30; and reverse, 50-TTGTCAGCCAAATGTTGCAT-30.
qPCR was performed in a total reaction of 25 ml with
23 HotStart PCR MasterMIX including SYBR Green I (KSI)
according to the manufacturers recommendations. qPCR
data were obtained with a Rotor-Gene 3000 instrument
(Corbett Research, LTF-Labortechnik). At the end of each
run, a melting curve analysis was performed to assess
nonspeciﬁc signals. Each sample was run in triplicate,
and the means were used for further calculations. Rela-
tive mRNA levels were quantiﬁed via the comparative
CT method. For normalization we used the geometric
mean of three internal control genes: beta-actin (ACTB
[MIM 102630]), glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH [MIM 138400]), and peptidyl-prolyl isom-
erase a (PPIA [MIM 123840]). Reference gene primers were
obtained from Promolgene.We showed that PDE8B expres-
sion is higher in putamen than in pallidum and total brain.
The putamen belongs to the striatum, which is affected by
ADSD. Peripheral tissues (adrenal gland, liver, skeletal86 The American Journal of Human Genetics 86, 83–87, January 8, 20muscle, skin ﬁbroblasts, leukocytes) showed a much lower
PDE8B expression (Figure 3).
In addition, we carried out qualitative RT-PCR for the
PDE8B isoforms in different brain regions. Primer
sequences are given in Table S6. Isoforms 2–6 are present
in putamen, pallidum, and total brain (Figure S1B). Because
isoform 1 contains no unique DNA sequences that are not
also present in other isoforms, it cannot be ampliﬁed by
RT-PCR without coamplifying other isoforms. Therefore,
its expression cannot be analyzed separately by RT-PCR.
In ADSD patients, all functional domains of PDE8B are
lost in isoforms1–5 (Figures 2B, 2D, and2E). Isoform6starts
with an alternative ﬁrst exon. Therefore, its amino acid
sequence remains unaffected by the mutation (Figure 2B).
To analyze the cellular localization of wild-type PDE8B
protein versus mutant PDE8B protein, we generated
a wild-type PDE8B expression vector tagged with cherry
red ﬂuorescent protein (pCherry-PDE8BWt) in addition
to the above-mentioned GFP-tagged constructs. pCherry
is a derivative of pEGFP-N3, in which we exchanged
EGFP for cherry ﬂuorescent protein. Next we performed
single transfections and cotransfections of NIH 3T3 and
HEK293 cells with pEGFP-PDE8BMut and pCherry-
PDE8BWt constructs and compared the subcellular locali-
zation via confocal microscopy. NIH 3T3 and HEK293 cells
were grown on coverslips and transfected as described
above. Cells were methanol ﬁxed 24 hr after transfection,
stained with DAPI (Roche), and mounted with Immu-
mount (Fisher Scientiﬁc). Images were acquired with
a confocal laser-scanner microscope (Zeiss LSM 510). We
did not observe any difference in the localization of wild-
type versus mutant protein (Figure S1C). The localization
of PDE8B wild-type and mutant clearly differed from that10
of an empty vector control, which was diffusely distributed
across the cytoplasm (data not shown). However, the local-
ization of the small mutated PDE8B protein might be
severely inﬂuenced by the large fused ﬂuorescent protein,
limiting the value of this analysis.
In summary, we show that a complex mutation in
PDE8B resulting in a frameshift leading to a severely trun-
cated, dysfunctional protein causes ADSD. ADSD is charac-
terized by dysfunction and morphological changes of the
striatal part of the basal ganglia. PDE8B could play an
important role in the regulation of neuronal function,
especially in the striatum. PDE8B regulates cAMP levels
and therefore might inﬂuence the dopaminergic neuro-
transmission in the striatum. Five subtypes of dopamine
receptors (DRD1-5 [MIM 126449-126453]) have been
described.7DRD1 andDRD2 receptors are highly expressed
in the striatum.8 DRD1 and DRDR5 receptors stimulate
cAMP synthesis and form the D1-like receptor family.
Receptors DRD2, DRD3, and DRD4 inhibit cAMP synthesis
and constitute the D2-like receptor family. Parkinson
disease is characterized by a lack of dopamine in the brain
and an excellent therapeutic response to L-Dopa. In
contrast, ADSD patients do not show a good L-Dopa
response. Taking into account that PDE8B degrades
cAMP, the second messenger of dopamine receptors, one
might speculate that ADSD is caused by a defect in dopa-
mine signaling downstream of the dopamine receptors.
Elucidating the causative genetic defects of monogenic
forms of common polygenic diseases and related disorders
has contributed eminently to understanding the pathome-
chanisms underlying Parkinson disease and other related
neurological disorders.9,10 We believe that the functional
analysis of PDE8B will help to elucidate the pathomechan-
ism of ADSD and will contribute to our understanding of
other related neurological disorders.
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